Innoviva, Inc. reports results for the quarter ended June 30 - Earnings Summary

Innoviva

05/08/2026 22:51

Innoviva, Inc. INVA.OQ reported a quarterly adjusted loss of $1.14​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 77 cents.  The mean expectation of five analysts for the quarter was for earnings of 44 cents per share. Wall Street expected results to range from 7 cents to 60 cents per share.
Revenue rose 19.3% to $119.59 million from a year ago; analysts expected $110.98 million. 
Innoviva, Inc.'s reported EPS for the quarter was a loss of $1.14​.
The company reported a quarterly loss of $83.42 million.
Innoviva, Inc. shares had fallen by 8.1% this quarter and gained 4.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 11.7% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Innoviva, Inc. is $39.00, about 46.5% above its last closing price of $20.86
This summary was machine generated from LSEG data August 5 at 09:51 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.44
-1.14
Missed
Mar. 31 2026 
0.39
-0.05
Missed
Dec. 31 2025 
0.55
1.94
Beat
Sep. 30 2025 
0.48
1.08
Beat